Literature DB >> 21919028

Inhibition of Granzyme B by PI-9 protects prostate cancer cells from apoptosis.

Manisha Ray1, Daniel R Hostetter, Carly R K Loeb, Jeffry Simko, Charles S Craik.   

Abstract

BACKGROUND: In order for tumors to grow and proliferate, they must avoid recognition by immune cells and subsequent death by apoptosis. Granzyme B (GrB), a protease located in natural killer cells, initiates apoptosis in target cells. Inhibition of GrB by PI-9, its natural inhibitor, can prevent apoptosis. Here we investigate whether PI-9 protects prostate cancer cells from apoptosis.
METHODS: The expression of PI-9 was quantified by qPCR in several prostate cancer cell lines, and GrB activity was tested in each cell line. PI-9 was overexpressed in LNCaP cells, which lack endogenous PI-9. Apoptosis was induced by natural killer cells in LNCaP cells that either contained or lacked PI-9, and the percent cell death was quantified. Lastly, PI-9 levels were examined by qPCR and immunohistochemistry in prostate tumor tissue.
RESULTS: Prostate cancer cell lines that expressed PI-9 could inhibit GrB. Overexpression of PI-9 protected LNCaP cells from natural killer cell-mediated apoptosis. Examination of the levels of PI-9 in tissue from prostate tumors showed that PI-9 could be upregulated in low grade tumors and stochastically dysregulated in high grade tumors. Additionally, PI-9 was found consistently in high grade prostatic intraepithelial neoplasia and atrophic lesions.
CONCLUSIONS: These results indicate that overexpression of PI-9 can protect prostate cancer cells from apoptosis, and this effect may occur in human prostate tumors. These findings imply that early prostatic inflammation may trigger this increase in PI-9. This suggests that PI-9 upregulation is needed early in tumor progression, before additional protective mechanisms are in place.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21919028      PMCID: PMC3401211          DOI: 10.1002/pros.21486

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  33 in total

Review 1.  Lymphocyte-mediated cytotoxicity.

Authors:  John H Russell; Timothy J Ley
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

Review 2.  The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal.

Authors:  Judy Lieberman
Journal:  Nat Rev Immunol       Date:  2003-05       Impact factor: 53.106

3.  Discovery of potent, selective human granzyme B inhibitors that inhibit CTL mediated apoptosis.

Authors:  Christopher A Willoughby; Herbert G Bull; Margarita Garcia-Calvo; Joanne Jiang; Kevin T Chapman; Nancy A Thornberry
Journal:  Bioorg Med Chem Lett       Date:  2002-08-19       Impact factor: 2.823

Review 4.  The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation.

Authors:  Cosimo De Nunzio; Gero Kramer; Michael Marberger; Rodolfo Montironi; William Nelson; Fritz Schröder; Alessandro Sciarra; Andrea Tubaro
Journal:  Eur Urol       Date:  2011-04-09       Impact factor: 20.096

5.  The granzyme B inhibitor, protease inhibitor 9, is mainly expressed by dendritic cells and at immune-privileged sites.

Authors:  B A Bladergroen; M C Strik; N Bovenschen; O van Berkum; G L Scheffer; C J Meijer; C E Hack; J A Kummer
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

6.  High numbers of granzyme B/CD8-positive tumour-infiltrating lymphocytes in nasopharyngeal carcinoma biopsies predict rapid fatal outcome in patients treated with curative intent.

Authors:  Joost J Oudejans; Hari Harijadi; J Alain Kummer; I Bing Tan; Elizabeth Bloemena; Jaap M Middeldorp; Belinda Bladergroen; Danny F Dukers; Wim Vos; Chris J L M Meijer
Journal:  J Pathol       Date:  2002-12       Impact factor: 7.996

7.  Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors.

Authors:  J P Medema; J de Jong; L T Peltenburg; E M Verdegaal; A Gorter; S A Bres; K L Franken; M Hahne; J P Albar; C J Melief; R Offringa
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

8.  The granzyme B inhibitor, PI-9, is present in endothelial and mesothelial cells, suggesting that it protects bystander cells during immune responses.

Authors:  M S Buzza; C E Hirst; C H Bird; P Hosking; J McKendrick; P I Bird
Journal:  Cell Immunol       Date:  2001-05-25       Impact factor: 4.868

9.  Modulators of inflammation use nuclear factor-kappa B and activator protein-1 sites to induce the caspase-1 and granzyme B inhibitor, proteinase inhibitor 9.

Authors:  Padma Kannan-Thulasiraman; David J Shapiro
Journal:  J Biol Chem       Date:  2002-08-12       Impact factor: 5.157

Review 10.  ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects--a review.

Authors:  Rosita L ten Berge; Joost J Oudejans; Gert J Ossenkoppele; Chris J L M Meijer
Journal:  J Pathol       Date:  2003-05       Impact factor: 7.996

View more
  6 in total

Review 1.  Designing the Sniper: Improving Targeted Human Cytolytic Fusion Proteins for Anti-Cancer Therapy via Molecular Simulation.

Authors:  Anna Bochicchio; Sandra Jordaan; Valeria Losasso; Shivan Chetty; Rodrigo Casasnovas Perera; Emiliano Ippoliti; Stefan Barth; Paolo Carloni
Journal:  Biomedicines       Date:  2017-02-17

Review 2.  Human Granzyme B Based Targeted Cytolytic Fusion Proteins.

Authors:  Precious Hlongwane; Neelakshi Mungra; Suresh Madheswaran; Olusiji A Akinrinmade; Shivan Chetty; Stefan Barth
Journal:  Biomedicines       Date:  2018-06-20

Review 3.  Pyroptosis: mechanisms and diseases.

Authors:  Pian Yu; Xu Zhang; Nian Liu; Ling Tang; Cong Peng; Xiang Chen
Journal:  Signal Transduct Target Ther       Date:  2021-03-29

Review 4.  Escaping Death: How Cancer Cells and Infected Cells Resist Cell-Mediated Cytotoxicity.

Authors:  Karoliina Tuomela; Ashley R Ambrose; Daniel M Davis
Journal:  Front Immunol       Date:  2022-03-23       Impact factor: 7.561

5.  Efficacy of an adapted granzyme B-based anti-CD30 cytolytic fusion protein against PI-9-positive classical Hodgkin lymphoma cells in a murine model.

Authors:  S Schiffer; H P Hansen; G Hehmann-Titt; M Huhn; R Fischer; S Barth; T Thepen
Journal:  Blood Cancer J       Date:  2013-03-22       Impact factor: 11.037

6.  A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer.

Authors:  Jing-Jing Wang; Michelle Kwan-Yee Siu; Yu-Xin Jiang; Thomas Ho-Yin Leung; David Wai Chan; Huo-Gang Wang; Hextan Yuen-Sheung Ngan; Karen Kar-Loen Chan
Journal:  Biomolecules       Date:  2021-11-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.